LaNova Medicines Zhejiang Co., Ltd. clinical trials
Acquired by Sino Biopharmaceutical Limited
The registry lists 3 studies whose lead sponsor is LaNova Medicines Zhejiang Co., Ltd.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Registry sponsor names on this page
- LaNova Medicines Zhejiang Co., Ltd.3 studies
Something wrong with this grouping? Tell us on the Sino Biopharmaceutical Limited page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Sino Biopharmaceutical Limited studies →
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Phase 2
Sponsor listed in the registry: LaNova Medicines Zhejiang Co., Ltd. · LaNova Medicines Zhejiang Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Active, not recruitingNCT06351020Phase 3
Sponsor listed in the registry: LaNova Medicines Zhejiang Co., Ltd. · LaNova Medicines Zhejiang Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Study of LM-302 in Patients With Advance Solid TumorsCompletedNCT05161390Phase 1/2
Sponsor listed in the registry: LaNova Medicines Zhejiang Co., Ltd. · LaNova Medicines Zhejiang Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group